Related Experiment Videos
Guidelines for management of the problem patient
1Department of Urology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.
Urology
|August 1, 1988
Summary
This study outlines a treatment approach for complicated lower urinary tract infections (UTIs), focusing on identifying pathogens like Klebsiella and using targeted antibiotic therapy. It details a regimen involving cephalosporins and nitrofurantoin macrocrystals to effectively treat infections while minimizing resistance and side effects.
Area of Science:
- Urology
- Infectious Diseases
- Pharmacology
Background:
- Lower urinary tract infections (UTIs) are common in women, often managed by primary care physicians.
- Problematic UTIs necessitate comprehensive evaluation to identify causative agents and underlying conditions.
- A case highlights Klebsiella as a pathogen in a complex UTI scenario.
Purpose of the Study:
- To present a management strategy for complicated lower UTIs.
- To detail a therapeutic regimen aimed at eradicating infection and preventing recurrence.
- To emphasize the importance of targeted antimicrobial therapy to minimize resistance and side effects.
Main Methods:
- A hypothetical case of Klebsiella UTI is presented.
- Initial treatment involved a seven-day course of cephalosporin.
- Follow-up included reculture and a subsequent regimen of nitrofurantoin macrocrystals for bladder-targeted therapy.
Main Results:
- The described regimen aims for a sterile urine culture post-treatment.
- Nitrofurantoin macrocrystals are used for prophylaxis, with a phased dosage reduction.
- The strategy addresses recurrent infections and specific patient populations.
Conclusions:
- Effective management of complicated UTIs requires pathogen identification and tailored treatment.
- A combination of initial broad-spectrum antibiotics followed by targeted, low-dose prophylaxis can be effective.
- This approach seeks to optimize treatment outcomes for UTIs in diverse patient groups, including the elderly and immunocompromised.